SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

TOVX

Theriva Biologics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Cash runway into Q1 2027 is very short for a clinical-stage company; monitor for financing or partnership announcements. VIRAGE2 enrollment completion and initial data in Q3 2027 are the next key catalysts.

DirectionNeutral
Confidencemedium
Horizonmonths

VCN-01

▲ Bullish Named in this press release
Impact
Phase
Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
Time to market
Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
Next catalyst
None dated

What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.1600
T+0 close · Nov 12, 2026 · via day close
Latest settled
−9.94%
T+1 · $0.1441
Vs SPY
−9.57%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $0.1600entry
  2. T+1 · 4d ago −9.94%α −9.57% · $0.1441
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics reported Q3 2026 net loss of $1.47M ($0.03 per share), narrower than the $4.36M loss a year ago, driven by a 76% drop in R&D spending after completing the VIRAGE Phase 2b trial. Cash of $8.5M provides runway only into Q1 2027, and the company completed the sale of its SYN-004 microbiome assets for $350K upfront plus milestones. The VIRAGE2 trial is expected to complete enrollment in Q4 2026 with initial data by Q3 2027.

Key Financial Metrics

EPS
−$0.03
Revenue
$0.00
est $0.00

Key Facts

  • Q3 2026 net loss $1.47M ($0.03 per share) vs $4.36M ($0.45) in Q3 2025
  • Cash and equivalents $8.5M as of Sep 30, 2026, down from $13.1M at Dec 31, 2025
  • Cash runway into Q1 2027
  • VIRAGE2 Phase 2a enrollment expected to complete Q4 2026, initial data by Q3 2027
  • SYN-004 (ribaxamase) and related assets sold to Biossil Labs for $350K upfront plus up to $91M milestones and royalties
  • General and administrative expenses fell 51% to $923K; R&D expenses fell 76% to $612K
  • Weighted average shares outstanding 45.9M vs 9.7M a year ago, reflecting significant dilution

Financial Impact

Cash burn of $4.6M over nine months; cash runway only into Q1 2027; upfront proceeds from asset sale $350K

cashnet lossdilution

Risk Factors

  • Cash runway only into Q1 2027, requiring near-term financing or strategic alternative
  • Significant dilution from share issuance (shares outstanding rose from 35.7M to 45.9M since Dec 2025)
  • No revenue; dependent on clinical trial success and regulatory milestones
  • SYN-004 sale milestones are contingent and uncertain

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401493

Track record

11 reports on TOVX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026